Raffaele Dante Caposiena Caro

Raffaele Dante Caposiena Caro

Auto-generated profile, based on publicly available information

Raffaele Dante Caposiena Caro

Department of Dermatology and Venerology University of Trieste Trieste Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
RCRaffaele Dante Caposiena Caro
Raffaele Dante Caposiena Caro
MCMaria Vittoria Cannizzaro
Maria Vittoria Cannizzaro
EBElisabetta Botti
Elisabetta Botti
CRCosimo Di Raimondo
Cosimo Di Raimondo
EMEleonora Di Matteo
Eleonora Di Matteo
LBLuca Bianchi
Luca Bianchi

16 February 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
SRSimone Ribero
Simone Ribero
ARAlice Ramondetta
Alice Ramondetta
GFG. Fabbrocini
G. Fabbrocini
VBVincenzo Bettoli
Vincenzo Bettoli
CPC. Potenza
C. Potenza
PDP. Dapavo
P. Dapavo

19 September 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
FLF. Lacarrubba
F. Lacarrubba
VDValentina Dini
Valentina Dini
Maddalena NapolitanoMaddalena Napolitano
Maddalena Napolitano
MVM. Venturini
M. Venturini
DCD.R. Caposiena Caro
D.R. Caposiena Caro
TGthe Italian Ultrasound Working Group
the Italian Ultrasound Working Group

10 December 2017 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
RCR.D. Caposiena Caro
R.D. Caposiena Caro
FSF.M. Solivetti
F.M. Solivetti
LBLuca Bianchi
Luca Bianchi

19 July 2020 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
RCR.D. Caposiena Caro
R.D. Caposiena Caro
EMElisa Molinelli
Elisa Molinelli
VBV. Brisigotti
V. Brisigotti
AOA. Offidani
A. Offidani
LBLuca Bianchi
Luca Bianchi

9 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MBMartina Burlando
Martina Burlando
Gabriella FabbrociniGabriella Fabbrocini
Gabriella Fabbrocini
Claudio MarascaClaudio Marasca
Claudio Marasca
PDPaolo Dapavo
Paolo Dapavo
ACAndrea Chiricozzi
Andrea Chiricozzi
APaurora parodi
aurora parodi
This study aimed to compare adalimumab originator vs. biosimilar in HS patients, and to evaluate the effect of a switch to a biosimilar, or a switch back to the originator, in terms of treatment ineffectiveness. Patients with a diagnosis of HS were enrolled from 14 Italian sites. Treatment ineffectiveness was measured using Hurley score. The major analyses were 1) comparison between the two treatment groups (non-switcher analysis), and 2) the cross-over trend of Hurley score between treatment switchers (switcher analysis). Cox and Poisson regression models were used to compare the treatment ineffectiveness between groups. A total of 326 patients were divided into four groups: 171 (52.5%) taking originator; 61 (18.7%) patients taking biosimilar; 66 (20.2%) switchers; 28 (8.6%) switchers from originator to biosimilar and switched. A greater loss of efficacy was observed in the group allocated to the biosimilar than the originator group. The switcher analysis showed an effectiveness loss in the biosimilar compared to the originator. These results seem to indicate that a switch from one drug to the other may lead to a greater risk of inefficacy. A return to the previous treatment also does not ensure efficaciousness.